New drug cocktail aims to control Hard-to-Treat lymphoma
NCT ID NCT04646395
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a combination of two drugs, acalabrutinib and tafasitamab, in 26 patients with marginal zone lymphoma that has come back or not responded to previous treatment. The goal is to see how well the combo shrinks or controls the cancer and to check for side effects. Patients receive treatment for up to 24 cycles and are followed for about 5 years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
acalabrutinib and tafasitamab
What this could lead to
If successful, this combination could offer a new, effective treatment option for patients with marginal zone lymphoma that has returned or not responded to prior therapy.
What could go wrong
This is a small, early-phase trial (26 patients) with no control group, so results may not be definitive. Side effects from the drug combination are possible and will be closely monitored.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MARGINAL ZONE LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ASST Spedali Civili di Brescia
Brescia, Italy
-
AUSL Ravenna U.O. Ematologia
Ravenna, 48121, Italy
-
Azienda Ospedaliera - IRCCS - Arcispedale Santa Maria Nuova
Reggio Emilia, Italy
-
Fondazione IRCCS - Istituto Nazionale dei Tumori
Milan, Italy
-
Fondazione IRCCS Cà Granda-Ospedale Maggiore Policlinico
Milan, Italy
-
Oncology Institute of Southern Switzerland
Bellinzona, 6500, Switzerland
-
Ospedale Maggiore della Carità
Novara, Italy
-
Ospedale di Circolo e Fondazione Macchi - ASST Sette Laghi
Varese, Italy
-
University of Wien
Vienna, 1190, Austria